



Q & M DENTAL GROUP (SINGAPORE) LIMITED
(Company Registration Number 200800507R)
(Incorporated in the Republic of Singapore)

EXERCISE OF CALL OPTION – COMPLETION

1. The board of directors (the "**Board**" or "**Directors**") of Q & M Dental Group (Singapore) Limited ("**Q & M**" or the "**Company**", and together with its subsidiaries, the "**Group**") refers to its announcements dated 23 April 2020, 5 July 2020 and 21 October 2021 (the "**Option Announcements**") in relation to, *inter alia*, the exercise by the Company's 51% subsidiary, Acumen Diagnostics Pte. Ltd. ("**ADPL**"), of the right to purchase (the "**Call Option**") from Dr. Ong Siew Hwa ("**Dr. Ong**") her 100% shareholding interest in Acumen Research Laboratories Pte. Ltd. ("**ARL**") pursuant to the option agreement dated 22 April 2020 ("**Option Agreement**") entered into with Dr. Ong.

Unless otherwise defined, all capitalised terms used herein shall bear the same meanings ascribed to them in the Option Announcements.

2. The Board wishes to update the shareholders of the Company that pursuant to the exercise of the Call Option, the acquisition by ADPL of ARL has been completed. Consequently, ARL has become a wholly-owned subsidiary of the ADPL and an indirect subsidiary of the Company. The acquisition of ARL was funded by the internal resources of the Group.
3. As disclosed in the Option Announcements, ARL is a Singapore-grown medical technology company principally engaged in the business of providing biomedical research and development services, developing rapid polymerase chain reaction (PCR) based, culture-independent molecular diagnostic tests with a focus on infectious diseases. ARL has developed a first-in-kind sepsis host response test called AcuSept and is also collaborating with a European company to distribute molecular diagnostic tests including PCR detection of bacteria and the associated antibiotic markers in ASEAN. In addition, ARL conducts clinical trials to validate the diagnostic tests developed by it and has further developed capability in manufacturing diagnostic tests. ARL is also the registered owner of several patents, including a technology in relation to the detection of sepsis biomarkers, which can be applied in the detection of sepsis due to COVID-19.
4. ADPL is presently involved in the business of researching, manufacturing, selling and distributing PCR diagnostic test kits, as well as conducting of laboratory testing, including but not limited to infectious diseases, cancer and COVID-19 (the "**Medical Diagnostics Business**").
5. The management team of the Group had carefully assessed the business of ARL over the past 18 months and had taken into consideration its market potential, patent positions, industry position and track record. The Company believes that the business of ARL complements the Medical Diagnostics Business and the acquisition of ARL by ADPL will add substantial synergy and value to growing the business of the Group. Given the potential synergies and efficiencies which will be created by the addition of ARL to the

business of the ADPL, with the integration of ARL's business into ADPL, the Company believes that acquisition of ARL by ADPL will be able to enhance the long-term interests of the Company and its shareholders, generating improved shareholder value.

6. The acquisition of ARL by ADPL is not expected to have a material impact on the net tangible assets per share and earnings per share of the Company for the financial year ending 31 December 2021.

By Order of the Board

Q & M Dental Group (Singapore) Limited

Vitters Sim
Chief Financial Officer
1 November 2021

For more information, please contact:

Chief Financial Officer

Vitters Sim
Tel: 6705 9888
Email: vitters@qnm.sg